Abstract. The prognosis of alveolar soft part sarcoma is poor, despite the slow growth of the tumor. A number of cases with spontaneous regression of this rare tumor have been reported. Although the mechanisms underlying spontaneous regression remain uncertain, local immune reaction may be a possible contributing factor. Immunohistochemical expression of human leukocyte antigen (HLA) class I, cluster of differentiation (CD) 3, CD4, CD8, CD20, CD45, CD56, CD68, CD138 and CD163 were assessed in a series of 10 alveolar soft part sarcomas, and the expression profiles were associated with patients' clinicopathological parameters. Expression of HLA class I was observed in almost all the tumor cells of all cases. CD8(+) cells were identified in all tumors with varying densities. Moderate infiltration of CD8(+) cells was detected in three patients; one of these patients survived with long-term tumor remission. Infiltration of CD10(+), CD20(+), CD56(+) or CD138(+) cells was not revealed in all tumors. Moderate-diffuse infiltration of CD163(+) cells was observed in all tumors. To the best of our knowledge, the present study represents the first report of intratumoral immune cells in alveolar soft part sarcoma. Frequent expression of HLA class I in tumor cells was observed. CD8(+) cells were identified at various densities and CD163(+) cells were observed in alveolar soft part sarcoma. Moderate infiltration of CD8(+) cells in patients with a good prognosis may indicate the antitumor effects of immune cells in alveolar soft part sarcoma.
Introduction
Alveolar soft part sarcoma is a morphologically and clinically distinct neoplasm, that was first termed and defined by Christopherson et al (1) , in 1952. The name ʻalveolarʼ was derived from its pseudo alveolar appearance, with clustered polygonal cells with eosinophilic cytoplasm (1) . Although the tissue origin of alveolar soft part sarcoma still remains unclear, molecular studies have revealed chromosomal rearrangements at translocation (X;17)(p11;q25), resulting in an alveolar soft part sarcoma critical region 1 (ASPSCR1) and transcription factor E3 (TFE3) gene fusion (2) (3) (4) . The alveolar soft part sarcoma tumor usually presents as a painless, slow growing mass without functional impairment (1) . Typically, there is a lack of symptoms, and it is easily overlooked, with metastasis to the lung or brain often the first signs of manifestation of the disease (5) (6) (7) (8) (9) (10) (11) (12) . Prognosis is poor despite the slow growth of the tumor (5) (6) (7) (8) (9) (10) (11) (12) . There has been partial initial success with tyrosine kinase inhibitors (13) (14) (15) , however, active systemic therapy has not been successful for the majority of patients with metastatic diseases (9, 15, 16) . This emphasizes the requirement for alternative treatments such as immunotherapy.
Cases with spontaneous regression of alveolar soft part sarcoma have previously been reported (17) (18) (19) . However, the mechanisms underlying the spontaneous regression of this type of tumor remain uncertain, and the local immune reaction is considered to be a possible causative factor (20) .
Previous studies have demonstrated efficacy of immunotherapeutic strategies against cancer, where antitumor cytotoxic T lymphocytes are induced by cancer vaccination (21) (22) (23) (24) . Antitumor responses are modulated by the recognition of immunogenic epitopes in the context of human leukocyte antigen (HLA) class I in the tumors (21 
Materials and methods
Patients. The present study was approved by the Institutional Review Boards of the Niigata University Hospital (Niigata, Japan) and Niigata Cancer Hospital (Niigata, Japan), and complies with the Declaration of Helsinki. Written informed consent was obtained from all patients and/or their families prior to enrollment in the present study. Between January, 1985 and December, 2014, 10 patients with alveolar soft part sarcoma were treated at the Niigata University Hospital and Niigata Cancer Hospital. Data from these patients were reviewed retrospectively. The demographic data for the patients are summarized in A total of 10 fields of view from each section were assessed by two researchers by light microscopy, and cells were counted manually. The immunohistochemical results were evaluated by semi-quantitative scoring, according to a previous report (23) as follows: +++, high density of positive cells in the fields; ++, moderate density and +, low density.
Result
Clinical course of the patients. At initial presentation, 7/10 patients had metastatic disease and 3/10 patients had developed metastasis following initial treatment. A thigh tumor with eight metastatic lung-nodules at presentation was identified in patient 10. This patient underwent wide local excision of the thigh tumor, but chemotherapy was not administered , as the patient's parents did not approve the additional cytotoxic treatment. For one year following excision of the primary tumor, the patient received monthly intravenous infusions containing 1x10 10 ex vivo expanded and interferon (IFN) α-treated peripheral blood mononuclear cells at another hospital (21) . All but one of the lung nodules slowly diminished in size in the six months following the initial surgery. Only one lung-nodule was detected by computed tomography, 24 months following surgery. The size of the lung tumor was stable, and endoscopic resection of the tumor was carried out nine years subsequent to the initial presentation. The patient was free of metastatic disease two years following the metastasectomy (Fig. 1) . In total, during the present study, seven patients succumbed to alveolar soft-part sarcoma, two patients survived with metastatic disease, and one patient survived and was free from cancer. (Figs. 2-4) ; these cells were interspersed within nests of tumor cells and the perivascular region. CD68 levels were analyzed in all tissue samples; however, precise measurements were difficult to obtain as inflammatory cells and numerous tumor cells were positive for this antigen. In case 10, the metastatic lung tumor cells were also positive for HLA class I, and moderate infiltration of CD8(+) cells was revealed in the metastatic tumor tissues ( Fig. 5 ; Table II) .
Discussion
Previous studies have demonstrated five cases of spontaneous regression of alveolar soft part sarcoma (Table III) , in which three of the five patients are Japanese (17) (18) (19) 25, 26) The high incidence of Japanese cases may due to language bias during literature review. All three Japanese patients remain alive following an extended period of remission, as determined by verbal communication with the patients. The spontaneous regression of sarcomas is rare and the actual incidence has not been reported (20) . Although the underlying mechanism of regression is not fully known, immune mechanisms have been demonstrated in certain types of cancer (20) .
The present study revealed moderate infiltration of CD8(+) lymphocytes in patient 10, who had long-term remission of multiple lung metastases, which suggests an anticancer immune response in this tumor. The specific immunotherapy treatment of this case is not known; however, diffuse infiltration of CD8(+) lymphocytes in the primary tumor prior to immunotherapy suggests specific immune components were activated. CD8(+) cells in malignant tumors have been associated with an improved survival rate for patients with various types of cancer, including non-small cell lung carcinoma, endometrial carcinoma, melanoma and Ewing sarcoma (20) . In the present study, the infiltration of CD10(+), CD20(+), CD56(+) or CD138(+) cells was not identified in all tissue samples. Therefore, B or natural killer cells do not dominate the immune response in alveolar soft-part sarcoma. The present study was designed to determine the expression levels of HLA class I and infiltration levels of immune cells in alveolar soft part sarcoma. It was revealed that the expression levels of HLA class I were preserved in all cases investigated in the current study. Previously, Tsukahara et al (27) investigated expression levels of HLA class I in bone and soft tissue tumors. Tsukahara et al (27) revealed that HLA class I was not expressed or was downregulated in 63% of bone and soft tissue tumor samples. Although the sample size in the current study is small, preservation of HLA class I expression and infiltration of CD8(+) lymphocytes in the tumor cells demonstrates noteworthy results in all cases. The results were concordant with those of previous studies, confirming the presence of an immune response in alveolar soft part sarcoma (28) . In addition, the diffuse infiltrations of CD8(+) lymphocytes in Patient  HLA class I  CD3  CD4  CD8  CD10  CD20  CD45  CD56  CD138  CD163   1  +++  ++  -++  --++  --+++  2  +++  +  +  +  --+  --+++  3  +++  +  -+  --+  --++  4  +++  +  -+  --+  --+++  5  +++  +  -+  --+  --++  6  +++  ++  +  ++  --++  --+++  7  +++  +  +  +  --+  --++  8  +++  +  +  +  --+  --+++  9 +++
+++, high density; ++, moderate density; +, low density; -, Negative; HLA, human leukocyte antigen; CD, cluster of differentiation. Table III Tumor-associated macrophages are stromal cells that are known to promote tumor invasion, metastasis and angiogenesis in numerous types of cancer (27) . The macrophages are able to produce and secrete growth factors, cytokines and other inflammatory mediators that may have important roles in tumor progression (29) . These tumor-activating functions are consistent with the results of previous clinical st9dies, demonstrating that the high macrophage density of various types of cancer is associated with a poor prognosis (29) . In addition, a previous study also demonstrated that macrophage infiltration is associated with poor prognosis in Ewing sarcoma (30) . However, a study of osteosarcoma revealed that macrophages were associated with a good clinical outcome (31) . The role of macrophages in sarcoma differs depending on the tumor subtype (31) . In the present study, CD163 macrophages infiltrated diffusely in all alveolar soft tissue tumor samples, similar to a previous study (28) . The prognostic value of macrophages in alveolar soft part sarcoma remains controversial. Additional studies are required to improve understanding of the role of macrophages in soft tissue tumors.
In conclusion, to the best of our knowledge, the present study represents the first report of intratumoral immune cell presence in alveolar soft part sarcoma. Frequent expression of HLA class I was revealed in the tumor cells. CD8(+) cells were identified at varying densities and CD163(+) cells were present in alveolar soft part sarcoma. Moderate infiltration of CD8(+) cells was observed in the tumors of patients with a Table III good prognosis, which may indicate the antitumor effect of immune cells in alveolar soft-part sarcoma.
